Consensus Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
139.4 USD +0.24% Intraday chart for Neurocrine Biosciences, Inc. +0.60% +5.83%

Evolution of the average Target Price on Neurocrine Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f3dab144ddd0683d9430aa552d5.WmjWUHb1mqRyIJKsXfd_vHbC6T9OVUZsuAzr5U1tdPU.FRG0JkSz_Mw2Z-SVD71NhT2Womt2InU1i3mPrDgjQLAxJ5VhIa_2lBoW3w~d4051470194da2eda394325781179ec4
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $200 From $170, Maintains Outperform Rating MT
UBS Adjusts Price Target on Neurocrine Biosciences to $159 From $128, Maintains Buy Rating MT
Deutsche Bank Raises Neurocrine Biosciences Price Target to $161 From $160, Maintains Buy Rating MT
Citigroup Trims Price Target on Neurocrine Biosciences to $140 From $141, Maintains Neutral Rating MT
Mizuho Securities Raises Price Target on Neurocrine Biosciences to $140 From $116, Maintains Neutral Rating MT
Wells Fargo Raises Price Target on Neurocrine Biosciences to $140 From $127, Maintains Equalweight Rating MT
Wedbush Adjusts Neurocrine Biosciences' Price Target to $147 From $141, Keeps Outperform Rating MT
Goldman Sachs Raises Price Target on Neurocrine Biosciences to $153 From $134, Maintains Buy Rating MT
Barclays Raises Neurocrine Biosciences' Price Target to $150 From $145, Maintains Overweight Rating MT
RBC Raises Price Target on Neurocrine Biosciences to $129 From $121, Keeps Sector Perform Rating MT
Stifel Adjusts Price Target on Neurocrine Biosciences to $144 From $141, Maintains Buy Rating MT
Wells Fargo Raises Price Target on Neurocrine Biosciences to $127 From $110, Keeps Equalweight Rating MT
Deutsche Bank Initiates Coverage on Neurocrine Biosciences With Buy Rating, $136 Price Target MT
UBS Adjusts Price Target on Neurocrine Biosciences to $128 From $135, Maintains Buy Rating MT
RBC Cuts Price Target on Neurocrine Biosciences to $121 From $128, Keeps Sector Perform Rating MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $170 From $165, Maintains Outperform Rating MT
Piper Sandler Adjusts Neurocrine Biosciences' Price Target to $100 From $95, Keeps Neutral Rating MT
Raymond James Adjusts Price Target on Neurocrine Biosciences to $145 From $135, Maintains Outperform Rating MT
RBC Boosts Price Target on Neurocrine Biosciences to $128 From $123, Keeps Sector Perform Rating MT
Wedbush Raises PT on Neurocrine Biosciences to $141 From $137 After 'Solid' Q3 Earnings, Maintains Outperform Rating MT
Jefferies Raises Neurocrine Biosciences Price Target to $139 From $136, Maintains Buy Rating MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $165 From $160, Maintains Outperform Rating MT
HC Wainwright Raises Price Target on Neurocrine Biosciences to $150 From $146, Maintains Buy Rating MT
Stifel Adjusts Price Target on Neurocrine Biosciences to $138 From $125, Maintains Buy Rating MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $160 From $154, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
139.4 USD
Average target price
151.4 USD
Spread / Average Target
+8.60%
High Price Target
200 USD
Spread / Highest target
+43.43%
Low Price Target
106 USD
Spread / Lowest Target
-23.98%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Neurocrine Biosciences, Inc.

Oppenheimer
UBS
Deutsche Bank Securities
Citigroup
Mizuho Securities
Wells Fargo Securities
Wedbush
Goldman Sachs
Barclays
RBC Capital Markets
Stifel Nicolaus
Piper Sandler
Raymond James
Jefferies & Co.
HC Wainwright
Canaccord Genuity
BMO Capital
JPMorgan Chase
Baird
Guggenheim
Evercore ISI
Morgan Stanley
SVB Securities LLC
Royal Bank of Canada
Cantor Fitzgerald
J.P. Morgan Chase
SVB Leerink
Credit Suisse
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings